- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- Dementia in the News
- Media Room
MedPage Today (April 2, 2014): Non-Amyloid Targets for Drug Development
What non-amyloid targets should be pursued for Alzheimer's disease therapies? We put the question to three well-known researchers in the field: Bradley Hyman, MD, PhD, of Massachusetts General Hospital in Boston; John Trojanowski, MD, PhD, of the University of Pennsylvania in Philadelphia; and Richard J. Caselli, MD, of the Mayo Clinic in Scottsdale, Ariz.
Their answers ranged from tau protein pathologies to apolipoprotein E to general neuroprotection.